Animal M-Stak
On sale on the US market (according to the DSLD)
Animal, food supplement from the US market
Animal M-Stak, a food supplement au code-barres 039442030283, is described by its US market label. If sold in France, it would be subject to 1 point of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Conditions légales
Trigonella foenum-graecum L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Animal
- Barcode
- 039442030283
- Form
- Other (for example, tea bag)
- One serving
- « 1 Pack(s) »
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Dicalcium Phosphate, Whey, Microcrystalline Cellulose, Gelatin, Stearic Acid, Magnesium Stearate, Titanium Dioxide, FD&C Blue #1, FD&C Red #40, Pharmaceutical Glaze
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Natural Flavone/Sterone Complex | Blend | 750 mg |
| Cyanotis vaga extract | Plant | not stated |
| 5-Methyl-7-Methoxyisoflavone | Other substance | not stated |
| Ajuga turkestanica extract | Plant | not stated |
| Phytosterols | Fat | not stated |
| Anti-Catabolic Amino Complex | Blend | 3,000 mg |
| L-Leucine | Amino acid | not stated |
| L-Isoleucine | Amino acid | not stated |
| L-Valine | Amino acid | not stated |
| L-Taurine | Other substance | not stated |
| Acetyl-L-Carnitine | Other substance | not stated |
| Anabolic Activator Complex | Blend | 1,000 mg |
| Ashwagandha extract (Withania somnifera) | Plant | not stated |
| Kudzu | Plant | not stated |
| Eleutherococcus senticosus (Eleutherococcus senticosus) | Plant | not stated |
| Insulin Potentiating Complex | Blend | 500 mg |
| Fenugreek (Trigonella foenum-graecum) | Plant | not stated |
| Banaba leaf extract (Lagerstroemia speciosa) | Plant | not stated |
| Cinnamon bark extract | Plant | not stated |
| Na-R-Alpha Lipoic Acid | Other substance | not stated |
| M Factor Complex with Bioperine | Blend | 500 mg |
| Ginger | Plant | not stated |
| Grapefruit (Citrus paradisi) | Plant | not stated |
| Piper nigrum fruit extract (Piper nigrum) | Plant | not stated |
| Energy Complex/Methylxanthine Complex | Blend | 500 mg |
| Caffeine | Other substance | not stated |
| Kola Nut | Plant | not stated |
| Guarana seed powder | Plant | not stated |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Animal M-Stak
Entered into DSLD on 21 December 2024. On sale on the US market (according to the DSLD).- Active ingredient added : Ajuga turkestanica Whole Plant Extract (quantity not stated)
- Active ingredient added : Ashwagandha Leaf, Root Extract (quantity not stated)
- Active ingredient added : Bioperine (quantity not stated)
- Active ingredient added : Cyanotis vaga Whole Plant Extract (quantity not stated)
- Active ingredient added : Guarana, Powder (quantity not stated)
- Active ingredient removed : Ajuga turkestanica extract (quantity not stated)
- Active ingredient removed : Ashwagandha extract (quantity not stated)
- Active ingredient removed : Cyanotis vaga extract (quantity not stated)
- Active ingredient removed : Guarana seed powder (quantity not stated)
- Active ingredient removed : Piper nigrum fruit extract (quantity not stated)
- Same quantity, different name: Anabolic Adaptogen Complex in this version; Anabolic Activator Complex on the displayed label (1,000 mg)
Official label: Animal M-Stak
Entered into DSLD on 22 October 2016. Withdrawn from the US market on 5 August 2015 (according to the DSLD).- Active ingredient added : Cinnamon bark powder (quantity not stated)
- Active ingredient added : Energy Complex (500 mg)
- Active ingredient added : Fenugreek extract (quantity not stated)
- Active ingredient added : Insulin Potentiating Complex with CinnulinPF (500 mg)
- Active ingredient added : Leucine Ethyl Ester Hydrochloride (quantity not stated)
- Active ingredient added : Methylxanthine Complex (quantity not stated)
- Active ingredient added : Muira Puama (quantity not stated)
- Active ingredient added : Safed Musli (quantity not stated)
- Active ingredient removed : Ashwagandha extract (quantity not stated)
- Active ingredient removed : Cinnamon bark extract (quantity not stated)
- Active ingredient removed : Energy Complex/Methylxanthine Complex (500 mg)
- Active ingredient removed : Fenugreek (quantity not stated)
- Active ingredient removed : Insulin Potentiating Complex (500 mg)
Official label: Animal M-Stak
Entered into DSLD on 24 March 2016. Withdrawn from the US market on 25 January 2021 (according to the DSLD).- Active ingredient added : Cinnamon bark powder (quantity not stated)
- Active ingredient added : Energy Complex (500 mg)
- Active ingredient added : Fenugreek extract (quantity not stated)
- Active ingredient added : Insulin Potentiating Complex with CinnulinPF (500 mg)
- Active ingredient added : Leucine Ethyl Ester Hydrochloride (quantity not stated)
- Active ingredient added : Methylxanthine Complex (quantity not stated)
- Active ingredient added : Muira Puama (quantity not stated)
- Active ingredient removed : Ashwagandha extract (quantity not stated)
- Active ingredient removed : Cinnamon bark extract (quantity not stated)
- Active ingredient removed : Energy Complex/Methylxanthine Complex (500 mg)
- Active ingredient removed : Fenugreek (quantity not stated)
- Active ingredient removed : Insulin Potentiating Complex (500 mg)
Official label: Animal M-Stak
Entered into DSLD on 23 January 2015. Withdrawn from the US market on 28 January 2016 (according to the DSLD).- Active ingredient added : Bioperine(R) (quantity not stated)
- Active ingredient added : Cinnulin PF (quantity not stated)
- Active ingredient added : Energy Complex (500 mg)
- Active ingredient added : Ginger root extract (quantity not stated)
- Active ingredient added : Kudzu extract (quantity not stated)
- Active ingredient added : Leucine Ethyl Ester Hydrochloride (quantity not stated)
- Active ingredient added : Methylxanthine Complex (quantity not stated)
- Active ingredient added : M Factor Complex (500 mg)
- Active ingredient added : Muira Puama (quantity not stated)
- Active ingredient added : Rhodiola rosea extract (quantity not stated)
- Active ingredient added : Safed Musli (quantity not stated)
- Active ingredient added : Theobromine (quantity not stated)
- Active ingredient removed : Ashwagandha extract (quantity not stated)
- Active ingredient removed : Cinnamon bark extract (quantity not stated)
- Active ingredient removed : Eleutherococcus senticosus (quantity not stated)
- Active ingredient removed : Energy Complex/Methylxanthine Complex (500 mg)
- Active ingredient removed : Ginger (quantity not stated)
- Active ingredient removed : Guarana seed powder (quantity not stated)
- Active ingredient removed : Kudzu (quantity not stated)
- Active ingredient removed : M Factor Complex with Bioperine (500 mg)
- Active ingredient removed : Piper nigrum fruit extract (quantity not stated)
Official label: Animal M-Stak
Entered into DSLD on 23 December 2011. Withdrawn from the US market on 9 September 2014 (according to the DSLD).- Active ingredient added : 4-Hydroxyisoleucine (quantity not stated)
- Active ingredient added : 6,7-Dihydroxybergmottin (quantity not stated)
- Active ingredient added : Beta-Sitosterol (quantity not stated)
- Active ingredient added : BioPerine (quantity not stated)
- Active ingredient added : Cinnulin PF (quantity not stated)
- Active ingredient added : Energy Complex (500 mg)
- Active ingredient added : Evodiamine (quantity not stated)
- Active ingredient added : Ginger root extract (quantity not stated)
- Active ingredient added : K-R-Alpha Lipoic Acid (quantity not stated)
- Active ingredient added : Kudzu extract (quantity not stated)
- Active ingredient added : Leucine Alpha Ketoglutarate (quantity not stated)
- Active ingredient added : Leucine Ethyl Ester (quantity not stated)
- Active ingredient added : Methylxanthine Complex (quantity not stated)
- Active ingredient added : M Factor Complex (500 mg)
- Active ingredient added : Muira Puama (quantity not stated)
- Active ingredient added : Rhodiola rosea extract (quantity not stated)
- Active ingredient added : Safed musli (quantity not stated)
- Active ingredient added : ß-Ecdysterone (quantity not stated)
- Active ingredient added : Theobromine (quantity not stated)
- Active ingredient added : Theophylline (quantity not stated)
- Active ingredient removed : Ashwagandha extract (quantity not stated)
- Active ingredient removed : Cinnamon bark extract (quantity not stated)
- Active ingredient removed : Cyanotis vaga extract (quantity not stated)
- Active ingredient removed : Eleutherococcus senticosus (quantity not stated)
- Active ingredient removed : Energy Complex/Methylxanthine Complex (500 mg)
- Active ingredient removed : Fenugreek (quantity not stated)
- Active ingredient removed : Ginger (quantity not stated)
- Active ingredient removed : Grapefruit (quantity not stated)
- Active ingredient removed : Guarana seed powder (quantity not stated)
- Active ingredient removed : Kola Nut (quantity not stated)
- Active ingredient removed : Kudzu (quantity not stated)
- Active ingredient removed : M Factor Complex with Bioperine (500 mg)
- Active ingredient removed : Na-R-Alpha Lipoic Acid (quantity not stated)
- Active ingredient removed : Phytosterols (quantity not stated)
- Active ingredient removed : Piper nigrum fruit extract (quantity not stated)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ashwagandha extract
Read the warning, when it applies and the studies cited
ASHWAGANDHA - WITHANIA SOMNIFERA
Route of administration: Oral
Cautions and warnings
Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
Sources cited by Health Canada (3)
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
- Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
Sources cited by Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
- Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.
- Eleutherococcus senticosus
Read the warning, when it applies and the studies cited
ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS
Route of administration: Oral (ESCOP 2003; Bradley 1992)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).
Sources cited by Health Canada (2)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.
Contraindications
Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).
Sources cited by Health Canada (5)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.
- Fenugreek
Read the warning, when it applies and the studies cited
FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).
Sources cited by Health Canada (4)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. An Evidence-Based Approach. New York (NY): Taylor and Francis; 2006.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Health Canada monograph dated 29 May 2026
FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Caffeine
Read the warning, when it applies and the studies cited
CAFFEINE
Route of administration: Oral (Higdon and Frei 2006)
Cautions and warnings
Applies to products providing 100 mg to 400 mg caffeine, per day1.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).
Sources cited by Health Canada (7)
- Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
- Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomised trial
- Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
- Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Review article
- Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Clinical trial
- Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analysis
- Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analysis
1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.
Applies to products providing more than 300 mg caffeine, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).
Sources cited by Health Canada (1)
- Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Additives and Contaminants 2003;20(1):1-30. PubMed Review article
Applies to products providing 400 mg or more caffeine, per day.
When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).
Sources cited by Health Canada (8)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clinic Proceeding 2005;80(4):541-545. PubMed Case report
- Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. The Annals of Pharmacotherapy 2006;40(1):53-57. PubMed Randomised trial
- FDA 2023: Food and Drug Administration. Title 21 Chapter 1 Part 340. Stimulant drug products for over-the-counter human use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services; 2023. [Accessed 2023 Aug 28]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=340&showFR=1
- Haller CA, Benowitz NL, Jacob P. Hemodynamic effects of ephedra-free weight-loss supplements in humans. The American Journal of Medicine 2005;118(9):998-1003. PubMed Randomised trial
- NIH 2004: National Institutes of Health. Office of Dietary Supplements. Fact sheets. Ephedra and ephedrine alkaloids for weight loss and athletic performance; 2004. [Accessed 2023 August 28]. Available from: https://ods.od.nih.gov/factsheets/ephedraandephedrine-HealthProfessional/.
- Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. Journal of Neurology, Neurosurgery and Psychiatry 2000;68(1):112-113. PubMed Case report
- Zimmerman DR. Zimmerman's Complete Guide to Nonprescription Drugs, 2nd edition. Detroit (MI): Gale Research Inc.; 1992.
Contraindications
Applies to products providing more than 400 mg caffeine per day.
Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).
Sources cited by Health Canada (7)
- Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
- Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomised trial
- Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
- Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Review article
- Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Clinical trial
- Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analysis
- Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analysis
Known adverse reactions
Condition of application: All products.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).
Sources cited by Health Canada (2)
Applies to products providing 200 mg or more caffeine, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).
Sources cited by Health Canada (1)
- Higgins JP, Babu KM, Caffeine reduces myocardial blood flow during exercise. The American Journal of Medicine 2013;126(8):730-e 1-8.
Applies to products providing more than 400 mg caffeine, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).
Sources cited by Health Canada (3)
- IOM 2001: Institute of Medicine. Committee on Military Nutrition Research, Food and Nutrition Board, Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academy Press; 2001 [Accessed 2023 Aug 28]. Available from: http://books.nap.edu/openbook.php?isbn=0309082587.
- Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49(1):37-50. PubMed Review article
- Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Safety 2001;24(15):1127-1142. PubMed Review article
Condition of application: All products except those making a diuretic claim1.
When using this product diuretic effect may occur.
1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Animal
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Animal M-Stak: composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/39442030283-animal-m-stak-animal, updated 25 March 2021.